- Home
- EYE vs GHRS Comparison
EYE vs GHRS Comparison
Compare EYE & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYE
- GHRS
- Stock Information
- Founded
- EYE 1990
- GHRS 2018
- Country
- EYE United States
- GHRS Ireland
- Employees
- EYE N/A
- GHRS N/A
- Industry
- EYE Ophthalmic Goods
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- EYE Health Care
- GHRS Health Care
- Exchange
- EYE Nasdaq
- GHRS Nasdaq
- Market Cap
- EYE 830.0M
- GHRS 868.7M
- IPO Year
- EYE 2017
- GHRS 2021
- Fundamental
- Price
- EYE $11.70
- GHRS $12.51
- Analyst Decision
- EYE Hold
- GHRS Strong Buy
- Analyst Count
- EYE 5
- GHRS 3
- Target Price
- EYE $13.40
- GHRS $35.67
- AVG Volume (30 Days)
- EYE 1.2M
- GHRS 1.1M
- Earning Date
- EYE 02-26-2025
- GHRS 03-07-2025
- Dividend Yield
- EYE N/A
- GHRS N/A
- EPS Growth
- EYE N/A
- GHRS N/A
- EPS
- EYE N/A
- GHRS N/A
- Revenue
- EYE $2,177,092,000.00
- GHRS N/A
- Revenue This Year
- EYE N/A
- GHRS N/A
- Revenue Next Year
- EYE $2.86
- GHRS N/A
- P/E Ratio
- EYE N/A
- GHRS N/A
- Revenue Growth
- EYE 20.66
- GHRS N/A
- 52 Week Low
- EYE $9.56
- GHRS $6.00
- 52 Week High
- EYE $24.11
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- EYE 50.81
- GHRS 51.44
- Support Level
- EYE $12.07
- GHRS $13.50
- Resistance Level
- EYE $12.88
- GHRS $14.91
- Average True Range (ATR)
- EYE 0.46
- GHRS 1.58
- MACD
- EYE 0.03
- GHRS -0.22
- Stochastic Oscillator
- EYE 40.18
- GHRS 5.56
About EYE National Vision Holdings Inc.
National Vision Holdings Inc is an optical retailer in the U.S. Its product portfolio includes eyeglasses and sunglasses, contact lenses, accessories, and other products. The company has two operating segments; Owned and Host segment includes company-owned brands America's Best and Eyeglass World, In America's Best stores, vision care services are provided by optometrists or by independent professional corporations and Host operating consist of Military and Fred Meyer which provide eye exams by independent optometrists, and the Legacy segment manages the operations of, and supplies inventory and lab processing services to Legacy retail Vision Centers. It earns a majority of its revenue from the Owned and Host segment.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.